Pulmonx

Pulmonx is a commercial-stage medical technology company focused on providing planning tools and treatments for obstructive lung disease. Pulmonx solution is comprised of the Zephyr® Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform, and is designed to address the need for a more effective, minimally invasive treatment option for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD).
Pulmonx stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Pulmonx balance sheet

Report period2018 2019 2020 2021 20222023
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Pulmonx cash flows

Report period2018 2019 2020 2021 20222023
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Pulmonx multipliers

Report period2018 2019 2020 2021 20222023
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/EBITDA adj.
EV/EBITDA
EV/EBITDA adj.

Pulmonx profitability

Report period2018 2019 2020 2021 20222023
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Pulmonx assets
Pulmonx cash flows

Pulmonx dividend policy

The company doesn't provide dividend

Pulmonx shares

TickerNameTypeNominal valueISINPrice
LUNG:USPulmonxCommon share-US7458481014$7.51
Pulmonx news
04.05.2022
Pulmonx's GAAP loss for the 3 months of 2022 was $15.828 million, up 26.5% from $12.512 million in the previous year. Revenues rose 16.7% to $10.785 million from $9.244 million a year earlier.
Source: {source} pictogram investors.pulmonx.com
Pictogram next
24.02.2022
Pulmonx's GAAP loss for 2021 was $48.661 million, up 51% from $32.231 million in the previous year. Revenue increased 47.9% to $48.416 million from $32.733 million a year earlier.
Source: {source} pictogram investors.pulmonx.com
Pictogram next
03.11.2021
Pulmonx reported a GAAP loss of $35.655 million for 9M 2021, up 55.5% from $22.934 million in the previous year. Revenues rose 51.5% to $34.708 million from $22.903 million a year earlier.
Source: {source} pictogram investors.pulmonx.com
Pictogram next
04.08.2021
Pulmonx reported a GAAP loss of $24.422 million for the six months of 2021, up 28% from $19.074 million in the previous year. Revenue increased 74.5% to $21.447 million from $12.291 million a year earlier.
Source: {source} pictogram investors.pulmonx.com
Pictogram next
All Pulmonx news
General information
Company namePulmonx
Tags#medtech
SectorHealth Care / Health Care Equipment & Services / Health Care Equipment & Supplies / Health Care Equipment
Business address700 Chesapeake Drive Redwood City, CA 94063 United States
Websiteinvestors.pulmonx.com
Information disclosurewww.sec.gov